Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient`s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 7 full-time employees. The firm is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The firm is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties.
Website: xeneticbio.com


  • Good financial results growth rate 33.6% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (25.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -69 117.1% (LTM)
  • Share price is 26.2% higher than minimum and 75.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (7.4x vs 6.1x)

Key Financials (Download financials)

Ticker: XBIO
Share price, USD:  (0.0%)2.55
year average price 3.09  


year start price 4.01 2025-02-15

max close price 10.36 2025-10-08

min close price 2.02 2025-12-17

current price 2.55 2026-02-14
Common stocks: 1 542 139

Dividend Yield:  0.0%
EV / Sales: -1.4x
Margin (EBITDA LTM / Revenue): -19.4%

Target EV / EBITDA (hist percentile): 6.1x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 4
Net Debt ($m): -4 122
EV (Enterprise Value): -4 118
EBITDA LTM (млн $): -556
Price to Book: 1.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-19accessnewswire.com

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

2025-11-13accessnewswire.com

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

2025-10-10accessnewswire.com

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

2025-05-14accessnewswire.com

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

2025-04-09accessnewswire.com

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

2024-12-17accesswire.com

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

2024-12-05accesswire.com

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

2024-11-22accesswire.com

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

2024-11-13accesswire.com

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

2024-10-17accesswire.com

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2023-11-09 2023-08-10 2023-05-11 2022-11-09 2022-08-11
acceptedDate 2025-11-12 16:30:51 2025-08-12 17:00:57 2025-03-18 16:30:22 2024-11-12 16:30:29 2024-08-13 16:32:41 2024-05-09 17:00:35 2024-04-26 16:30:38 2023-11-09 17:00:42 2023-08-10 16:30:48 2023-05-11 16:30:48 2023-04-28 16:30:12 2022-11-09 16:30:40 2022-08-11 17:00:49 2022-03-22 17:20:50 2021-04-28 17:00:09
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 1M 589 897 3M 614 243 726 404 510 816 3M 611 174 651 005 605 844 2M 414 250 416 710 1M 436 942
costOfRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
grossProfit 1M 589 897 3M 614 243 726 404 510 816 3M 611 174 651 005 605 844 2M 414 250 416 710 1M 436 942
grossProfitRatio 1 1 1 1 1 1 1 1 1 1
researchAndDevelopmentExpenses 756 482 656 557 3M 367 985 933 771 944 321 3M 1M 903 243 595 276 5M 398 803 2M 3M 2M
generalAndAdministrativeExpenses 815 209 657 752 3M 745 731 1M 834 910 4M 737 241 945 950 925 743 4M 863 233 1M 4M 3M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 815 209 657 752 3M 745 731 1M 834 910 4M 737 241 945 950 925 743 4M 863 233 1M 4M 3M
otherExpenses -1 0 0 0 0 52 0 -666 21 122 4520 0 0 -1076 0 9M
operatingExpenses 2M 1M 7M 1M 2M 2M 7M 2M 2M 2M 8M 1M 3M 7M 14M
costAndExpenses 2M 1M 7M 1M 2M 2M 7M 2M 2M 2M 8M 1M 3M 7M 14M
interestIncome 30 783 34 232 249 861 61 298 63 447 73 249 355 757 91 796 126 103 54 101 167 152 45 475 15 965 100 467 126 171
interestExpense 0 0 0 0 0 0 0 0 -58 621 0 -43 769 0 0 0
depreciationAndAmortization -13 237 0 153 336 0 0 -10 624 0 7640 2857 0 27 043 7956 9612 35 482 28 837
ebitda -523 176 -724 412 -4M -499 473 -1M -1M -5M -1M -1M -915 175 -7M -839 830 -3M -6M -5M
ebitdaratio -0.509 -1.228 -0.813 -1.841 -2.483 -1.876 -1.841 -1.511 -2.027 -6.39
operatingIncome -544 734 -724 412 -4M -499 473 -1M -1M -5M -1M -1M -915 175 -7M -847 786 -3M -6M -14M
operatingIncomeRatio -0.53 -1.228 -0.813 -1.841 -2.483 -1.876 -1.841 -1.511 -2.047 -6.448
totalOtherIncomeExpensesNet 34 795 35 709 244 153 62 802 63 426 73 297 381 137 -666 21 122 58 621 165 555 43 769 -1076 101 586 125 679
incomeBeforeTax -509 939 -688 703 -4M -436 671 -1M -1M -4M -1M -1M -856 554 -7M -804 017 -3M -6M -14M
incomeBeforeTaxRatio -0.497 -1.167 -0.711 -1.754 -2.34 -1.727 -1.614 -1.414 -1.941 -6.413
incomeTaxExpense 0 0 0 0 0 10 624 0 -99 436 -128 960 -58 621 0 -43 769 0 0 -3M
netIncome -509 939 -688 703 -4M -436 671 -1M -1M -4M -1M -1M -797 933 -7M -760 248 -3M -6M -11M
netIncomeRatio -0.497 -1.167 -0.711 -1.754 -2.34 -1.727 -1.614 -1.317 -1.835 -6.413
eps -0.33 -0.45 -2.57 -0.28 -0.83 -0.78 -2.71 -0.69 -0.69 -0.53 -4.49 -0.053 -0.19 -5.39 -17.04
epsdiluted -0.33 -0.45 -0.28 -0.83 -0.78 -0.69 -0.69 -0.53 -0.053 -0.19
weightedAverageShsOut 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 1M 14M 14M 1M 639 238
weightedAverageShsOutDil 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 1M 14M 14M 1M 639 238
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-18 2024-04-26 2023-04-28 2022-03-22 2021-04-28
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 249 861 355 757 167 152 100 467 126 171
ebit -4M -5M -7M -6M -5M
nonOperatingIncomeExcludingInterest 0 0 0 0 -9M
netIncomeFromContinuingOperations -4M -4M -7M -6M -11M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -4M -4M -7M -6M -11M
epsDiluted -2.57 -2.71 -4.49 -5.39 -17.04

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2023-11-09 2023-08-10 2023-05-11 2022-11-09 2022-08-11
acceptedDate 2025-11-12 16:30:51 2025-08-12 17:00:57 2025-03-18 16:30:22 2024-11-12 16:30:29 2024-08-13 16:32:41 2024-05-09 17:00:35 2024-04-26 16:30:38 2023-11-09 17:00:42 2023-08-10 16:30:48 2023-05-11 16:30:48 2023-04-28 16:30:12 2022-11-09 16:30:40 2022-08-11 17:00:49 2022-03-22 17:20:50 2021-04-28 17:00:09
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 4M 5M 6M 7M 7M 8M 9M 10M 11M 12M 13M 14M 15M 18M 12M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 4M 5M 6M 7M 7M 8M 9M 10M 11M 12M 13M 14M 15M 18M 12M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 946 361 573 854 0 188 088 227 999 552 042 603 828 1M 1M 876 539 0 319 103 448 733 227 043 0
totalCurrentAssets 5M 5M 7M 7M 8M 8M 10M 11M 12M 13M 14M 14M 15M 19M 12M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0 27 043
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 313 921 1M 1M 1M 1M 704 431 704 431 844 431 1M 1M 1M 1M 782 942
totalNonCurrentAssets 0 0 313 921 1M 1M 1M 1M 704 431 704 431 844 431 1M 1M 1M 1M 809 985
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0
totalAssets 5M 5M 7M 8M 9M 9M 11M 12M 13M 14M 15M 16M 16M 20M 13M
accountPayables 578 250 346 828 283 615 243 343 283 586 210 483 240 832 448 558 221 281 259 180 287 360 202 778 472 699 362 470 327 396
shortTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 533 525 556 602 34 203 766 064 1M 506 011 48 256 619 939 650 034 597 185 39 949 848 080 806 484 0 0
totalCurrentLiabilities 1M 903 430 894 263 1M 2M 716 494 809 585 1M 871 315 856 365 1M 1M 1M 1M 936 928
longTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 259 180 0 -202 778 0 0 0
totalNonCurrentLiabilities 0 0 0 0 0 0 0 0 0 259 180 0 202 778 472 699 0 27 043
otherLiabilities 0 0 0 0 0 0 0 0 0 -259 180 0 -202 778 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 27 043 62 525
totalLiabilities 1M 903 430 894 263 1M 2M 716 494 809 585 1M 871 315 856 365 1M 1M 1M 1M 963 971
preferredStock 0 1804 1804 0 1804 1804 1804 2774 2774 2774 2774 2774 2774 2774 2774
commonStock 1545 1545 1545 1545 1544 1544 1544 1536 1536 15 192 1520 14 342 14 342 13 465 8771
retainedEarnings -199M -199M -197M -196M -196M -194M -193M -192M -191M -190M -189M -188M -187M -183M -177M
accumulatedOtherComprehensiveIncomeLoss 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734 253 734
othertotalStockholdersEquity 203M 203M 203M 203M 203M 203M 203M 203M 202M 202M
totalStockholdersEquity 4M 4M 6M 7M 7M 9M 10M 11M 12M 13M 14M 15M 15M 18M 12M
totalEquity 4M 4M 6M 7M 7M 9M 10M 11M 12M 13M 14M 15M 15M 18M 12M
totalLiabilitiesAndStockholdersEquity 5M 5M 8M 9M 9M 12M 13M 14M 16M 16M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 5M 5M 7M 8M 9M 9M 11M 12M 13M 14M 15M 16M 16M 20M 13M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 27 043 62 525
netDebt -4M -5M -6M -7M -7M -8M -9M -10M -11M -12M -13M -14M -15M -18M -11M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-18 2024-04-26 2023-04-28 2022-03-22 2021-04-28
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 421 954 0 556 094 252 356 841 958
totalPayables 283 615 240 832 287 360 362 470 327 396
otherPayables 0 0 0 0 0
accruedExpenses 576 445 520 497 745 847 1M 574 050
capitalLeaseObligationsCurrent 0 0 0 27 043 35 482
capitalLeaseObligationsNonCurrent 0 0 0 0 27 043
treasuryStock -5M -5M -5M -5M -5M
additionalPaidInCapital 208M 208M 208M 206M 194M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO XBIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2023-11-09 2023-08-10 2023-05-11 2022-11-09 2022-08-11
acceptedDate 2025-11-12 16:30:51 2025-08-12 17:00:57 2025-05-13 16:30:32 2024-11-12 16:30:29 2024-08-13 16:32:41 2024-05-09 17:00:35 2024-04-26 16:30:38 2023-11-09 17:00:42 2023-08-10 16:30:48 2023-05-11 16:30:48 2023-04-28 16:30:12 2022-11-09 16:30:40 2022-08-11 17:00:49 2022-03-22 17:20:50 2021-04-28 17:00:09
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -509 939 -688 703 -4M -436 671 -1M -1M -4M -1M -1M -856 554 -7M -804 017 -3M -6M -11M
depreciationAndAmortization 0 0 0 0 0 0 0 0 0 0 27 043 7956 9612 35 482 28 837
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 -24 269 -3M
stockBasedCompensation 0 15 683 171 814 27 536 42 096 77 074 283 085 70 266 69 389 68 852 511 480 137 364 135 870 410 437 468 914
changeInWorkingCapital -164 162 289 190 970 983 -665 464 706 770 -41 306 -262 726 35 655 -287 546 -314 736 -426 685 -420 571 492 809 461 193 -52 449
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 208 345 235 503 84 678 -578 195 871 108 -93 091 -263 571 197 182 14 950 -216 791 -347 947 -228 325 215 915 457 132 -378 111
otherWorkingCapital -372 507 53 687 886 305 -87 269 -164 338 51 785 845 -161 527 -302 496 -97 945 -78 738 -192 246 0 4061 325 662
otherNonCashItems 15 854 0 0 615 562 0 170 165 0 0 0 0 2M 0 0 24 269 9M
netCashProvidedByOperatingActivities -658 247 -383 830 -3M -459 037 -525 104 -1M -4M -949 634 -1M -1M -5M -1M -728 899 -5M -4M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 -500 000 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 0 0 0 0 0
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 0 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 0 0 0 0 0 0
netCashUsedProvidedByFinancingActivities 0 0 0 0 0 0 0 0 0 0
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -658 247 -383 830 -3M -459 037 -525 104 -1M -4M -949 634 -1M -1M -5M -1M -1M 7M 1M
cashAtEndOfPeriod 4M 5M 6M 7M 7M 8M 9M 10M 11M 12M 13M 14M 15M 18M 12M
cashAtBeginningOfPeriod 5M 5M 9M 7M 8M 9M 13M 11M 12M 13M 18M 15M 16M 12M 10M
operatingCashFlow -658 247 -383 830 -3M -459 037 -525 104 -1M -4M -949 634 -1M -1M -5M -1M -728 899 -5M -4M
capitalExpenditure -3 0 0 0 0 0 -1 0 0 0 -500 000 0 0 0 0
freeCashFlow -658 250 -383 830 -3M -459 037 -525 104 -1M -4M -949 634 -1M -1M -5M -1M -1M -5M -4M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-05-13 2024-04-26 2023-04-28 2022-03-22 2021-04-28
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities 0 0 -500 000 0 0
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 0 11M 5M
netCommonStockIssuance 0 0 0 11M 5M
commonStockIssuance 0 0 0 11M 5M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 3679 0
netCashProvidedByFinancingActivities 0 0 0 11M 5M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-11-13 08:45 ET
Xenetic Biosciences published news for 2025 q3
SEC form 8
2025-11-13 08:45 ET
Xenetic Biosciences published news for 2025 q3
SEC form 10
2025-11-12 16:30 ET
Xenetic Biosciences reported for 2025 q3
SEC form 8
2025-10-14 12:48 ET
Xenetic Biosciences published news for 2025 q3
SEC form 8
2025-10-14 12:48 ET
Xenetic Biosciences published news for 2025 q3
SEC form 8
2025-10-14 12:48 ET
Xenetic Biosciences published news for 2025 q3
SEC form 8
2025-10-14 12:48 ET
Xenetic Biosciences published news for 2025 q3
SEC form 8
2025-08-13 12:00 ET
Xenetic Biosciences published news for 2025 q2
SEC form 8
2025-08-13 12:00 ET
Xenetic Biosciences published news for 2025 q2
SEC form 10
2025-08-12 21:00 ET
Xenetic Biosciences reported for 2025 q2
SEC form 8
2025-05-14 00:00 ET
Xenetic Biosciences published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Xenetic Biosciences published news for 2025 q1
SEC form 10
2025-05-13 21:00 ET
Xenetic Biosciences published news for 2025 q1
SEC form 10
2025-05-13 00:00 ET
Xenetic Biosciences reported for 2025 q1
SEC form 8
2025-04-10 12:00 ET
Xenetic Biosciences published news for 2025 q1
SEC form 8
2025-04-10 12:00 ET
Xenetic Biosciences published news for 2025 q1
SEC form 8
2025-03-19 00:00 ET
Xenetic Biosciences published news for 2024 q4
SEC form 8
2025-03-19 00:00 ET
Xenetic Biosciences published news for 2024 q4
SEC form 10
2025-03-18 20:30 ET
Xenetic Biosciences published news for 2024 q4
SEC form 10
2025-03-18 00:00 ET
Xenetic Biosciences reported for 2024 q4
SEC form 8
2024-11-13 08:30 ET
Xenetic Biosciences published news for 2024 q3
SEC form 8
2024-11-13 08:30 ET
Xenetic Biosciences published news for 2024 q3
SEC form 10
2024-11-12 16:30 ET
Xenetic Biosciences reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Xenetic Biosciences published news for 2024 q3
SEC form 8
2024-08-14 00:00 ET
Xenetic Biosciences published news for 2024 q2
SEC form 8
2024-08-14 00:00 ET
Xenetic Biosciences published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Xenetic Biosciences reported for 2024 q2
SEC form 8
2024-05-10 00:00 ET
Xenetic Biosciences published news for 2024 q1
SEC form 8
2024-05-10 00:00 ET
Xenetic Biosciences published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
Xenetic Biosciences reported for 2024 q1
SEC form 8
2024-03-22 08:00 ET
Xenetic Biosciences published news for 2023 q4
SEC form 8
2024-03-22 08:00 ET
Xenetic Biosciences published news for 2023 q4
SEC form 10
2024-03-21 17:00 ET
Xenetic Biosciences reported for 2023 q4
SEC form 10
2024-03-21 00:00 ET
Xenetic Biosciences published news for 2023 q4
SEC form 8
2023-11-13 00:00 ET
Xenetic Biosciences published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Xenetic Biosciences reported for 2023 q3
SEC form 6
2023-08-11 08:05 ET
Xenetic Biosciences published news for 2023 q2
SEC form 8
2023-08-11 00:00 ET
Xenetic Biosciences published news for 2023 q2
SEC form 10
2023-08-10 16:30 ET
Xenetic Biosciences reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Xenetic Biosciences published news for 2023 q2
SEC form 6
2023-05-12 12:30 ET
Xenetic Biosciences published news for 2023 q1
SEC form 6
2023-05-11 16:31 ET
Xenetic Biosciences published news for 2023 q1
SEC form 10
2023-05-11 16:30 ET
Xenetic Biosciences published news for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Xenetic Biosciences reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Xenetic Biosciences published news for 2023 q1
SEC form 6
2023-04-28 16:30 ET
Xenetic Biosciences published news for 2023 q1
SEC form 6
2023-03-23 07:30 ET
Xenetic Biosciences published news for 2022 q4
SEC form 8
2023-03-23 00:00 ET
Xenetic Biosciences published news for 2022 q4
SEC form 10
2023-03-22 16:30 ET
Xenetic Biosciences reported for 2022 q4
SEC form 10
2023-03-22 00:00 ET
Xenetic Biosciences published news for 2022 q4
SEC form 6
2022-12-22 16:30 ET
Xenetic Biosciences published news for 2022 q3
SEC form 6
2022-12-09 16:30 ET
Xenetic Biosciences published news for 2022 q3
SEC form 6
2022-12-02 17:00 ET
Xenetic Biosciences published news for 2022 q3
SEC form 6
2022-11-10 07:05 ET
Xenetic Biosciences published news for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Xenetic Biosciences published news for 2022 q3
SEC form 10
2022-11-09 16:30 ET
Xenetic Biosciences reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Xenetic Biosciences reported for 2022 q3
SEC form 6
2022-10-17 17:00 ET
Xenetic Biosciences published news for 2022 q3
SEC form 6
2022-10-12 17:00 ET
Xenetic Biosciences published news for 2022 q3
SEC form 6
2022-10-03 17:12 ET
Xenetic Biosciences published news for 2022 q3
SEC form 6
2022-08-12 08:00 ET
Xenetic Biosciences published news for 2022 q2
SEC form 8
2022-08-12 00:00 ET
Xenetic Biosciences published news for 2022 q2
SEC form 10
2022-08-11 17:00 ET
Xenetic Biosciences reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Xenetic Biosciences reported for 2022 q2
SEC form 6
2022-07-07 09:00 ET
Xenetic Biosciences published news for 2022 q2
SEC form 6
2022-06-06 16:30 ET
Xenetic Biosciences published news for 2022 q1
SEC form 10
2022-05-12 16:06 ET
Xenetic Biosciences reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Xenetic Biosciences reported for 2022 q1
SEC form 6
2022-04-28 16:26 ET
Xenetic Biosciences published news for 2022 q1
SEC form 6
2022-04-27 06:30 ET
Xenetic Biosciences published news for 2022 q1
SEC form 6
2022-03-23 08:30 ET
Xenetic Biosciences published news for 2021 q4
SEC form 8
2022-03-23 00:00 ET
Xenetic Biosciences published news for 2021 q4
SEC form 10
2022-03-22 17:20 ET
Xenetic Biosciences published news for 2021 q4
SEC form 10
2022-03-22 00:00 ET
Xenetic Biosciences published news for 2021 q4
SEC form 6
2021-12-09 17:00 ET
Xenetic Biosciences published news for 2021 q3
SEC form 6
2021-11-19 16:55 ET
Xenetic Biosciences published news for 2021 q3
SEC form 6
2021-11-16 08:30 ET
Xenetic Biosciences published news for 2021 q3
SEC form 6
2021-11-12 08:00 ET
Xenetic Biosciences published news for 2021 q3
SEC form 10
2021-11-12 07:45 ET
Xenetic Biosciences published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Xenetic Biosciences published news for 2021 q3
SEC form 8
2021-11-12 00:00 ET
Xenetic Biosciences published news for 2021 q3
SEC form 6
2021-10-15 17:00 ET
Xenetic Biosciences published news for 2021 q3
SEC form 6
2021-10-15 16:30 ET
Xenetic Biosciences published news for 2021 q3
SEC form 6
2021-09-13 07:00 ET
Xenetic Biosciences published news for 2021 q2
SEC form 6
2021-08-13 08:05 ET
Xenetic Biosciences published news for 2021 q2
SEC form 8
2021-08-13 00:00 ET
Xenetic Biosciences published news for 2021 q2
SEC form 10
2021-08-12 16:31 ET
Xenetic Biosciences published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Xenetic Biosciences published news for 2021 q2
SEC form 6
2021-07-28 14:24 ET
Xenetic Biosciences published news for 2021 q2
SEC form 6
2021-07-16 16:30 ET
Xenetic Biosciences published news for 2021 q2
SEC form 6
2021-05-12 07:00 ET
Xenetic Biosciences published news for 2021 q1
SEC form 10
2021-05-11 17:00 ET
Xenetic Biosciences published news for 2021 q1
SEC form 10
2021-05-11 00:00 ET
Xenetic Biosciences published news for 2021 q1
SEC form 6
2021-04-28 17:00 ET
Xenetic Biosciences published news for 2021 q1
SEC form 6
2021-03-17 08:00 ET
Xenetic Biosciences published news for 2020 q4
SEC form 10
2021-03-16 17:13 ET
Xenetic Biosciences published news for 2020 q4
SEC form 6
2021-01-19 08:00 ET
Xenetic Biosciences published news for 2020 q4
SEC form 6
2020-12-16 09:00 ET
Xenetic Biosciences published news for 2020 q3
SEC form 6
2020-12-14 11:15 ET
Xenetic Biosciences published news for 2020 q3
SEC form 6
2020-12-09 17:00 ET
Xenetic Biosciences published news for 2020 q3
SEC form 6
2020-11-13 08:00 ET
Xenetic Biosciences published news for 2020 q3
SEC form 10
2020-11-12 17:15 ET
Xenetic Biosciences published news for 2020 q3
SEC form 6
2020-10-30 17:00 ET
Xenetic Biosciences published news for 2020 q3
SEC form 6
2020-10-13 16:30 ET
Xenetic Biosciences published news for 2020 q3
SEC form 6
2020-09-30 16:45 ET
Xenetic Biosciences published news for 2020 q2